Gardasil Goes To FDA; Merck Hopes For Mid-Year Approval Of HPV Vaccine
Executive Summary
Merck could have a strong case for priority review of its human papillomavirus vaccine Gardasil
You may also be interested in...
GSK Takes “Blank Check” Approach To Pursuit Of Biotech Agreements
GlaxoSmithKline will continue to actively build its biotech business with further product in-licensing and acquisitions, CEO J.P. Garnier indicated
Merck Initiates Gardasil Detailing; Campaign To Focus On Cancer Prevention
Merck has begun detailing its pending human papilloma virus vaccine Gardasil to non-routine vaccinators, the company reported Dec. 15 during an annual business review in Whitehouse Station, N.J
Merck Initiates Gardasil Detailing; Campaign To Focus On Cancer Prevention
Merck has begun detailing its pending human papilloma virus vaccine Gardasil to non-routine vaccinators, the company reported Dec. 15 during an annual business review in Whitehouse Station, N.J